Dr. Marc Bernstein, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (1981)
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 658
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1981Medical school: Tulane University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
LA license 016053 -
Specialist
LA license 016053
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ochsner Medical Center Acute New Orleans, LA
- Slidell Memorial Hospital Slidell, LA
- St Tammany PArish Hospital Covington, LA
- North Oaks Medical Center Hammond, LA
- St Bernard PArish Hospital Chalmette, LA
Medical groups
- Cardiovascular Specialty Care Center of Covington, LLC (8 clinicians)
- Iteld Bernstein and Associates LLC (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 658
- Services billed
- 7,108
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, inclisiran, 1 mg | 8,236 | 15 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,601 | 619 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,507 | 608 |
| Injection, regadenoson, 0.1 mg | 385 | 100 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 337 | 332 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 330 | 185 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 178 | 67 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 140 | 30 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 136 | 52 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 118 | 115 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Metoprolol Succinate Other prescribers in Slidell, LA | 1,256 |
| Atorvastatin Calcium Other prescribers in Slidell, LA | 1,232 |
| Rosuvastatin Calcium Other prescribers in Slidell, LA | 851 |
| Amlodipine Besylate Other prescribers in Slidell, LA | 824 |
| Eliquis (apixaban) Other prescribers in Slidell, LA | 773 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Slidell, LA | 722 |
| Lisinopril Other prescribers in Slidell, LA | 711 |
| Carvedilol Other prescribers in Slidell, LA | 688 |
| Losartan Potassium Other prescribers in Slidell, LA | 656 |
| Ezetimibe Other prescribers in Slidell, LA | 563 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 110 payments worth $1,973 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $438 |
|---|---|
| Novartis Pharmaceuticals Corporation | $281 |
| Pfizer Inc. | $214 |
| Merck Sharp & Dohme LLC | $203 |
| Novo Nordisk Inc | $134 |
| Abbott Laboratories | $113 |
| Amgen Inc. | $90.24 |
| Scpharmaceuticals Inc. | $72.88 |
| Food and Beverage | $1,973 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 7 companies. The companies reported $428,786 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fi…
Janssen Research & Development, LLC - EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in partici…
Boehringer Ingelheim International GmbH - Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Amgen Inc. - EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in partici…
Boehringer Ingelheim Pharma GmbH & Co.kg - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Amgen Inc. - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly…
Amgen Inc. - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.